Why Is Rhythm Pharma Stock Jumping Today?

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM ) stock is trading higher on Monday after the company reported preliminary results from an ongoing Phase 2 study evaluating setmelanotide in patients with Prader-Willi syndrome (PWS). The six-month data shared on Saturday showed improvements in body mass index , body composition, hyperphagia, and behavioral measures. The company presented the findings at the Endocrine Society’s Annual Meeting, ENDO 2026. data-variant="card" data-news-mode="manual" > Read Also: Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy The trial enrolled 18 patients between the ages of 6 and 23 who met obesity-related eligibility criteria. As of June 12, 2026, 17 participants remained on active treatment in the 52-week study. BMI And Body Composition Trends Show Improvement According to the six-month analysis, patients receiving setmelanotide recorded a Full story available on Benzinga.com